Clinical evaluation of amitraz as a treatment for canine demodicosis

Abstract A liquid concentrate formulation of amitraz was clinically evaluated in 1721 canines showing demodicosis, by 25 veterinary investigators. The therapy was applied topically at 14-day intervals, and at a concentration of 250 ppm active drug in water. The miticide was efficacious and safe; approximately 99% of the canines showing localized or generalized demodicosis became clinically normal, and the side-effects recorded were minimal and transient. Approximately 3 4 of the patients were pure-bred animals and the majority were less than 1 year old. The clinical data support the conclusion that amitraz (liquid concentrate) is efficacious and safe for treating canine demodicosis.